FDA Approves Dupixent to Treat Eczema

Share this content:
FDA Approves Dupixent to Treat Eczema
FDA Approves Dupixent to Treat Eczema

WEDNESDAY, March 29, 2017 (HealthDay News) -- Dupixent (dupilumab) has been approved by the U.S. Food and Drug Administration to treat moderate-to-severe eczema that isn't well controlled by topical medication.

The active ingredient in Dupixent is an antibody (dupilumab) that binds to a protein (interleukin-4 receptor alpha subunit) that causes inflammation, and is administered subcutaneously. Its effectiveness was evaluated in clinical studies involving 2,119 patients for whom topical medication hadn't worked. Overall, participants who received Dupixent achieved clear or almost clear skin and a reduction in itch after 16 weeks of treatment.

The most common side effects included injection-site reactions, cold sores, and eye inflammation. More serious adverse effects included severe allergic reactions, conjunctivitis, and keratitis.

"FDA's approval of Dupixent demonstrates our commitment to approving new and innovative therapies for patients with skin disease," Julie Beitz, M.D., director of the Office of Drug Evaluation III in the FDA's Center for Drug Evaluation and Research, said in a statement. "Eczema can cause significant skin irritation and discomfort for patients, so it is important to have a variety of treatment options available to patients, including those patients whose disease is not controlled by topical therapies."

The FDA granted approval of Dupixent to Regeneron Pharmaceuticals.

More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease



Sign up for myCME e-newsletters




More in Home

Medicaid Expansion Ups Preemptive Listing for Kidney Transplant

Medicaid Expansion Ups Preemptive Listing for Kidney Transplant

From pre- to post-expansion period, 59 percent relative increase in Medicaid-covered preemptive listings

BCG Vaccine Tied to Reduced Hyperglycemia in Type 1 Diabetes

BCG Vaccine Tied to Reduced Hyperglycemia in Type ...

Systemic shift in glucose metabolism from oxidative phosphorylation to aerobic glycolysis

Many Physicians Not Prepared for End-of-Life Talks With Patients

Many Physicians Not Prepared for End-of-Life Talks With ...

Additional training, reimbursement may foster these critical conversations, authors say

is free, fast, and customized just for you!




Already a member?

Sign In Now »